Patent · US Active

Agent that increases the expression of the opioid kappa 1 for the treatment of cancer

US11351165B2 · kind B2 · utility

0Cited by

3References

15Claims

0Family size

Assignee

LDN Pharma Limited · GB

Inventors

Angus Dalgleish · London, GB
Wai Lui · Sha Tin, CN

Key dates

Filing date	Mar 28, 2018
Grant date	Jun 7, 2022
Priority date	—
Expiry date	Mar 28, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/9486
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dose dependent, where the greater the induced expression of OPRK1, the greater the cytotoxicity of the chemotherapeutic agent. The increase in overall cytotoxicity is independent of the cytotoxicity of the agent that increases the expression of OPRK1, which itself has no or minimal cytotoxic effect.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.